Infections in patients with cancer undergoing chemotherapy

Aetiology, prevention, and treatment

Research output: Contribution to journalReview article

79 Citations (Scopus)

Abstract

Patients with cancer who are undergoing chemotherapy are highly susceptible, especially if neutropenic, to almost any type of bacterial or fungal infection. These infections cause substantial morbidity and mortality. Prophylactic use of antibiotics should be avoided, however, since this practice is associated with a risk of emergence of resistant bacteria and it does not lower the risk of death. However, chemoprophylaxis has a role for candidal fungal infections. Because infection in a neutropenic host can be rapidly fatal if not treated, the empirical administration of broadspectrum intravenous antibiotics is generally indicated for these patients, and the local frequencies, susceptibility, and resistance patterns of various pathogens must be taken into account. Once therapy has been initiated, changes in antibiotic regimens during the first 5 days are useless unless the patient's clinical condition deteriorates substantially. The treatment of invasive fungal infections is particularly difficult. Many unsolved questions remain, and studies are proposed here that may shed light on these issues.

Original languageEnglish
Pages (from-to)595-604
Number of pages10
JournalThe Lancet Oncology
Volume4
Issue number10
DOIs
Publication statusPublished - Oct 1 2003
Externally publishedYes

Fingerprint

Mycoses
Anti-Bacterial Agents
Drug Therapy
Infection
Neoplasms
Chemoprevention
Bacterial Infections
Intravenous Administration
Therapeutics
Morbidity
Bacteria
Mortality
Invasive Fungal Infections

ASJC Scopus subject areas

  • Oncology

Cite this

Infections in patients with cancer undergoing chemotherapy : Aetiology, prevention, and treatment. / Vento, Sandro; Cainelli, Francesca.

In: The Lancet Oncology, Vol. 4, No. 10, 01.10.2003, p. 595-604.

Research output: Contribution to journalReview article

@article{47e26e742f2a483ab99439d1c847b859,
title = "Infections in patients with cancer undergoing chemotherapy: Aetiology, prevention, and treatment",
abstract = "Patients with cancer who are undergoing chemotherapy are highly susceptible, especially if neutropenic, to almost any type of bacterial or fungal infection. These infections cause substantial morbidity and mortality. Prophylactic use of antibiotics should be avoided, however, since this practice is associated with a risk of emergence of resistant bacteria and it does not lower the risk of death. However, chemoprophylaxis has a role for candidal fungal infections. Because infection in a neutropenic host can be rapidly fatal if not treated, the empirical administration of broadspectrum intravenous antibiotics is generally indicated for these patients, and the local frequencies, susceptibility, and resistance patterns of various pathogens must be taken into account. Once therapy has been initiated, changes in antibiotic regimens during the first 5 days are useless unless the patient's clinical condition deteriorates substantially. The treatment of invasive fungal infections is particularly difficult. Many unsolved questions remain, and studies are proposed here that may shed light on these issues.",
author = "Sandro Vento and Francesca Cainelli",
year = "2003",
month = "10",
day = "1",
doi = "10.1016/S1470-2045(03)01218-X",
language = "English",
volume = "4",
pages = "595--604",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "10",

}

TY - JOUR

T1 - Infections in patients with cancer undergoing chemotherapy

T2 - Aetiology, prevention, and treatment

AU - Vento, Sandro

AU - Cainelli, Francesca

PY - 2003/10/1

Y1 - 2003/10/1

N2 - Patients with cancer who are undergoing chemotherapy are highly susceptible, especially if neutropenic, to almost any type of bacterial or fungal infection. These infections cause substantial morbidity and mortality. Prophylactic use of antibiotics should be avoided, however, since this practice is associated with a risk of emergence of resistant bacteria and it does not lower the risk of death. However, chemoprophylaxis has a role for candidal fungal infections. Because infection in a neutropenic host can be rapidly fatal if not treated, the empirical administration of broadspectrum intravenous antibiotics is generally indicated for these patients, and the local frequencies, susceptibility, and resistance patterns of various pathogens must be taken into account. Once therapy has been initiated, changes in antibiotic regimens during the first 5 days are useless unless the patient's clinical condition deteriorates substantially. The treatment of invasive fungal infections is particularly difficult. Many unsolved questions remain, and studies are proposed here that may shed light on these issues.

AB - Patients with cancer who are undergoing chemotherapy are highly susceptible, especially if neutropenic, to almost any type of bacterial or fungal infection. These infections cause substantial morbidity and mortality. Prophylactic use of antibiotics should be avoided, however, since this practice is associated with a risk of emergence of resistant bacteria and it does not lower the risk of death. However, chemoprophylaxis has a role for candidal fungal infections. Because infection in a neutropenic host can be rapidly fatal if not treated, the empirical administration of broadspectrum intravenous antibiotics is generally indicated for these patients, and the local frequencies, susceptibility, and resistance patterns of various pathogens must be taken into account. Once therapy has been initiated, changes in antibiotic regimens during the first 5 days are useless unless the patient's clinical condition deteriorates substantially. The treatment of invasive fungal infections is particularly difficult. Many unsolved questions remain, and studies are proposed here that may shed light on these issues.

UR - http://www.scopus.com/inward/record.url?scp=0141963140&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141963140&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(03)01218-X

DO - 10.1016/S1470-2045(03)01218-X

M3 - Review article

VL - 4

SP - 595

EP - 604

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 10

ER -